PRALUENT CROSS License & COMMERCIALIZATION AGREEMENT By and Between SANOFI BIOTECHNOLOGY SAS and REGENERON PHARMACEUTICALS, INC. Dated as of April 5, 2020Cross License & Commercialization Agreement • August 5th, 2020 • Regeneron Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS PRALUENT CROSS LICENSE & COMMERCIALIZATION AGREEMENT (this “Agreement”), dated as of April 5, 2020 (the “Execution Date”), and effective as of April 1, 2020 (the “Transition Date”), by and between SANOFI BIOTECHNOLOGY SAS, a société par actions simplifiée organized under the laws of France and having a principal place of business at 54 rue La Boétie, 75008 Paris, France (“Sanofi”), and REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”) (with each of Sanofi and Regeneron referred to herein individually as a “Party” and collectively as the “Parties”).
